戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d in livers of animal models and humans with polycystic liver disease.
2      Mutations in polycystins are a cause of polycystic liver disease.
3 tal diseases including Alagille Syndrome and polycystic liver disease.
4 gous gene models of human autosomal dominant polycystic liver disease.
5 ibitors might be used to treat patients with polycystic liver disease.
6 ese proteins might inhibit cyst expansion in polycystic liver disease.
7 regulator of cell proliferation may underlie polycystic liver disease.
8 mortalized B lymphoblasts from patients with polycystic liver disease.
9 mic reticulum (ER), cause autosomal dominant polycystic liver disease.
10 hen mutated, causes human autosomal dominant polycystic liver disease.
11 presents a potential therapeutic approach in polycystic liver disease.
12 ogenic variants sometimes resulted in severe polycystic liver disease.
13 cyst epithelium of a subset of patients with polycystic liver disease.
14         Mutations in PC2 are associated with polycystic liver diseases.
15 ts with breast abnormalities, 1 patient with polycystic liver disease, 1 patient with esophageal thic
16                           Autosomal dominant polycystic liver disease (ADPLD) is a distinct clinical
17 nical profile of isolated autosomal dominant polycystic liver disease (ADPLD) using nonaffected famil
18  one of the genes causing autosomal dominant polycystic liver disease (ADPLD).
19 ficant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in signi
20 imary cilia to treat EGFR-driven diseases in polycystic liver disease and cholangiocarcinoma.
21 ons have been linked to disorders, including polycystic liver disease and cholangiocarcinoma.
22  in vitro key features of Alagille syndrome, polycystic liver disease and cystic fibrosis (CF)-associ
23 have been associated with autosomal dominant polycystic liver disease and implicated in ADPKD, while
24 e previously been described in patients with polycystic liver disease and in some cases cystic kidney
25 olycystic kidney disease, autosomal dominant polycystic liver disease, and the third form of ADPKD.
26 al history, manifestations, and treatment of polycystic liver disease are based on the disease as it
27 underdiagnosed and genetically distinct from polycystic liver disease associated with ADPKD but with
28 y-eight of the 49 individuals diagnosed with polycystic liver disease before participation in the stu
29                                       Severe polycystic liver disease can complicate adult dominant p
30 ith extensive hepatic involvement with adult polycystic liver disease can have an excellent outcome w
31 ylase 6 inhibitors in cholangiocarcinoma and polycystic liver disease cells demonstrated synergistic
32                                              Polycystic liver disease, commonly associated with polyc
33                                           In polycystic liver diseases, cyst formation involves chola
34 whereas in isolated PCLD (autosomal dominant polycystic liver disease), disrupted cell adhesion may b
35 lysis of a randomized trial of patients with polycystic liver disease due to ADPKD, lanreotide for 12
36 osomal dominant polycystic kidney disease or polycystic liver disease; efficacy does not depend on si
37 hird gene yielding isolated liver cysts (the polycystic liver disease gene).
38 ative or indeterminate diagnosis, those with polycystic liver disease had slightly higher levels of s
39 hort of 265 patients with autosomal dominant polycystic liver disease harboring pathogenic variants i
40        Surgical intervention for symptomatic polycystic liver disease has been associated with signif
41 hich resulted in a slow, progressive form of polycystic liver disease in adult mice.
42   Mutations in the gene encoding SEC63 cause polycystic liver disease in humans; however, it is not c
43 al presentation and histological features of polycystic liver disease in the presence or absence of A
44 ycystic kidney disease or autosomal dominant polycystic liver disease, indicating that there are comm
45 pies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and oth
46                                 Genetically, polycystic liver disease is a heterogeneous disorder wit
47                           Autosomal dominant polycystic liver disease is a rare condition with a fema
48                                              Polycystic liver disease is a well described manifestati
49                      Hepatic cystogenesis in polycystic liver disease is associated with increased le
50                 Recently, we discovered that polycystic liver disease is caused by mutations in the p
51                           Autosomal dominant polycystic liver disease is characterized by the presenc
52               Clinically, autosomal dominant polycystic liver disease is characterized by vast hetero
53                                              Polycystic liver disease is genetically linked to protei
54                                              Polycystic liver disease is the most common extrarenal m
55                                              Polycystic liver disease may complicate autosomal domina
56 resent a therapeutic route for patients with polycystic liver disease, most of whom would not be amen
57 ion and biochemical properties of normal and polycystic liver disease mutant forms of hepatocystin we
58 ns were solitary giant liver cysts (n = 16), polycystic liver disease (n = 9), hydatid cyst (n = 6),
59 al hepatic fibrosis (two), cystinosis (one), polycystic liver disease (one), A-1-A deficiency (one),
60 ng mutation in hepatocystin observed in some polycystic liver disease patients produces a protein tha
61 seen in the rare inherited disorder isolated polycystic liver disease (PCLD) and are recognized as th
62                Dominantly inherited isolated polycystic liver disease (PCLD) consists of liver cysts
63                                              Polycystic liver disease (PCLD) is characterized by cyst
64                                              Polycystic liver disease (PCLD) is characterized by the
65 mains the curative treatment for symptomatic Polycystic Liver Disease (PCLD) patients and is associat
66                            For patients with polycystic liver disease (PCLD), nonsurgical treatments
67 of resective and fenestration procedures for polycystic liver disease (PCLD), we present the first se
68  hepatocystin (80K-H, PRKCSH), gives rise to polycystic liver disease (PCLD).
69                                           In polycystic liver diseases (PCLDs), increased cholangiocy
70 resent review summarizes recent knowledge on polycystic liver diseases (PCLDs), mechanisms of hepatic
71 gulation is a key feature of cystogenesis in polycystic liver diseases (PCLDs).
72         A group of genetic diseases known as polycystic liver disease (PLD) are distinguished by the
73                                 Treatment of polycystic liver disease (PLD) focuses on symptom improv
74                                              Polycystic liver disease (PLD) is a member of the cholan
75                                              Polycystic liver disease (PLD) is a rare disorder freque
76                                              Polycystic liver disease (PLD) is characterized by defec
77               Liver transplantation (LT) for polycystic liver disease (PLD) is rare, extremely challe
78 c tools or biomarkers are urgently needed in polycystic liver disease (PLD) to monitor disease progre
79 ical trials have shown that in patients with polycystic liver disease (PLD), short-term treatment wit
80             In polycystic kidney disease and polycystic liver disease (PLD), the normally nonprolifer
81                      In patients with severe polycystic liver disease (PLD), there is a need for new
82 ncreased level of intracranial aneurysms and polycystic liver disease (PLD), which can be severe and
83 cystins (PC1 or PC2/TRPP2) cause progressive polycystic liver disease (PLD).
84 apies for polycystic kidney disease (PKD) or polycystic liver disease (PLD).
85                                              Polycystic liver diseases (PLD) are inherited disorders
86                                              Polycystic liver diseases (PLDs) are genetic disorders c
87 malized age-adjusted total liver volumes and polycystic liver disease-related hospitalization (liver
88 sion is associated with the greatest odds of polycystic liver disease-related hospitalization.
89                           Autosomal dominant polycystic liver disease results from mutations in PRKCS
90               The laparoscopic management of polycystic liver disease should be reserved for patients
91                                              Polycystic liver diseases, the most important of which a
92 ly unresolved clinical diagnosis of ADPKD or polycystic liver disease to identify a candidate gene, A
93 d from healthy individuals and patients with polycystic liver disease to reproduce the effects of the
94 s analysis, we studied the 175 patients with polycystic liver disease with hepatic cysts identified b
95       We ascertained two large families with polycystic liver disease without kidney cysts and perfor